Innovative Vaccine Tech Jurata is at the forefront of vaccine innovation with its focus on cold chain-free biologics and biologics manufacturing acceleration, presenting opportunities to collaborate or supply advanced materials and manufacturing solutions.

Growth Through Funding Having secured significant seed funding and a key $1 million joint grant, Jurata demonstrates strong financial backing and growth potential, making it a promising partner for suppliers of biotech equipment, materials, and funding opportunities.

Strategic Collaborations Partnerships with organizations like CEPI and Gates-funded initiatives position Jurata as a key player in global health efforts, creating opportunities to engage with government agencies, NGOs, and global health initiatives.

Room-Temperature Solutions Jurata's development of wafer-like, room-temperature stable mRNA films for needle-free delivery opens avenues for companies specializing in storage, distribution, and innovative delivery technologies.

Expanding Market Focus With research targeting needle-free, easy-to-store vaccines, Jurata is well-positioned in the growing biologics and vaccine markets, offering opportunities to partner with companies providing consumer-friendly delivery platforms and global distribution networks.